Brolucizumab

Drug Profile

Brolucizumab

Alternative Names: ESBA-1008; RTH-258

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ESBATech
  • Developer Alcon
  • Class Antibodies; Eye disorder therapies; Immunoglobulin Fv fragments; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic macular oedema; Wet age-related macular degeneration

Most Recent Events

  • 03 Apr 2017 Novartis intends to submit NDA to the US FDA for Diabetic macular oedema in 2020
  • 01 Dec 2016 Phase-III clinical trials in Diabetic macular oedema in USA (Intravitreous) (Novartis 20-F 2016)
  • 01 Sep 2016 Alcon completes a phase II trial for Wet age-related macular degeneration in USA (NCT02507388)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top